What we do
Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability.
Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.
Who we are - History
Making biologics available & affordable to all through technology innovation
Key figures
- 2013 Incorporation Date
- 5 companies 1 Group with 4 affiliates
- 15.000m2 New offices in Jumet
- 350+ Dedicated people
Latest News
Project MADIBA - Groundbreaking partners…
An innovative new partnership was announced today to revolutionize access to COVID-19 and other vaccines in Africa by manufacturing these va…
Belgium: EIB boosts innovative biotech c…
• €30 million loan agreement for a new COVID-19 vaccine manufacturing facility in Wallonia (Belgium) and for the co-development of a pipelin…
Univercells unveils new brand identity a…
Brussels, Belgium, June 30, 2021 Univercells S.A. (the “Company”) announces a rebranding of its visual identity and update of its mission t…
Univercells and Exothera announce Thibau…
Univercells S.A. (“Univercells”) and Exothera S.A. (the “Company”) are pleased to announce that effective June 1, 2021, Thibault Jonckheere…